Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:25:48.694Z.
Calculation as of: 2026-10-06T16:25:48.694Z.
Quote observation: 2026-10-06T16:25:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Aura Biosciences, Inc.
Market Cap
$635.27M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$633.99M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$632.18M
Operating Cash Flow Yield
N/A
TTM Avg
0.02%
3Y Avg
0.02%
5Y Avg
0.02%
Market Cap
$650.93M
Operating Cash Flow Yield
N/A
TTM Avg
2.08%
3Y Avg
1.21%
5Y Avg
1.21%
Market Cap
$605.11M
Operating Cash Flow Yield
0.51%
TTM Avg
0.73%
3Y Avg
0.72%
5Y Avg
1.01%
Market Cap
$670.10M
Operating Cash Flow Yield
6.89%
TTM Avg
9.30%
3Y Avg
5.99%
5Y Avg
5.99%
Market Cap
$600.01M
Operating Cash Flow Yield
30.93%
TTM Avg
16.53%
3Y Avg
24.40%
5Y Avg
19.97%
Market Cap
$670.70M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$588.32M
Operating Cash Flow Yield
N/A
TTM Avg
1.57%
3Y Avg
5.72%
5Y Avg
13.10%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $635.27M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $633.99M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $632.18M | N/A | 0.02% | 0.02% | 0.02% |
| OmniAb, Inc. (OABI)vs › | $650.93M | N/A | 2.08% | 1.21% | 1.21% |
| AngioDynamics, Inc. (ANGO)vs › | $605.11M | 0.51% | 0.73% | 0.72% | 1.01% |
| MiMedx Group, Inc. (MDXG)vs › | $670.10M | 6.89% | 9.30% | 5.99% | 5.99% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | 30.93% | 16.53% | 24.40% | 19.97% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $670.70M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $588.32M | N/A | 1.57% | 5.72% | 13.10% |
| Annexon, Inc. (ANNX)vs › | $678.13M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
